Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 23, 2008. The report details a specific corporate action regarding a share buyback executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share repurchases.
- Shares Purchased: 1,660,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,129.13 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.05% of total voting rights).
- Shares in Issue: 5,348,700,004 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's share capital through the cancellation of 1,660,000 shares purchased on May 23, 2008. Consequently, the number of shares held in Treasury increased to 484,194,158. The filing text does not provide comparative data against prior periods for these specific metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules. No specific risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the total number of shares in issue (5,348,700,004) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (484,194,158) and its impact on total voting rights (9.05%).
- Review the Annual General Meeting minutes from May 21, 2008, to understand the full scope of the share buyback authority utilized.